WO2024005758A1 - A stable oral liquid composition comprising terbutaline & guaifenesin - Google Patents
A stable oral liquid composition comprising terbutaline & guaifenesin Download PDFInfo
- Publication number
- WO2024005758A1 WO2024005758A1 PCT/TR2023/050605 TR2023050605W WO2024005758A1 WO 2024005758 A1 WO2024005758 A1 WO 2024005758A1 TR 2023050605 W TR2023050605 W TR 2023050605W WO 2024005758 A1 WO2024005758 A1 WO 2024005758A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oral liquid
- liquid composition
- present
- terbutaline
- guaifenesin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 89
- 239000007788 liquid Substances 0.000 title claims abstract description 50
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 title claims abstract description 36
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 229960002146 guaifenesin Drugs 0.000 title claims abstract description 33
- 229960000195 terbutaline Drugs 0.000 title claims abstract description 31
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims abstract description 22
- 229940001584 sodium metabisulfite Drugs 0.000 claims abstract description 22
- 235000010262 sodium metabisulphite Nutrition 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000002738 chelating agent Substances 0.000 claims abstract description 14
- 208000006673 asthma Diseases 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 206010011224 Cough Diseases 0.000 claims abstract description 8
- 230000029058 respiratory gaseous exchange Effects 0.000 claims abstract description 7
- 206010006482 Bronchospasm Diseases 0.000 claims abstract description 6
- 208000024891 symptom Diseases 0.000 claims abstract description 5
- 206010008469 Chest discomfort Diseases 0.000 claims abstract description 4
- 208000000059 Dyspnea Diseases 0.000 claims abstract description 4
- 206010013975 Dyspnoeas Diseases 0.000 claims abstract description 4
- 208000037656 Respiratory Sounds Diseases 0.000 claims abstract description 4
- 206010047924 Wheezing Diseases 0.000 claims abstract description 4
- 230000007885 bronchoconstriction Effects 0.000 claims abstract description 4
- 208000013220 shortness of breath Diseases 0.000 claims abstract description 4
- 239000012535 impurity Substances 0.000 claims description 37
- 230000003647 oxidation Effects 0.000 claims description 21
- 238000007254 oxidation reaction Methods 0.000 claims description 21
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 claims description 8
- 229960005105 terbutaline sulfate Drugs 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 235000003599 food sweetener Nutrition 0.000 claims description 6
- 239000003002 pH adjusting agent Substances 0.000 claims description 6
- 239000003765 sweetening agent Substances 0.000 claims description 6
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000003172 expectorant agent Substances 0.000 description 8
- 230000003419 expectorant effect Effects 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 7
- 229960005150 glycerol Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 6
- 235000010234 sodium benzoate Nutrition 0.000 description 6
- 239000004299 sodium benzoate Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 5
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229960003885 sodium benzoate Drugs 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- -1 sulfate salt Chemical class 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 3
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 241000220223 Fragaria Species 0.000 description 3
- 235000016623 Fragaria vesca Nutrition 0.000 description 3
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 3
- 229960002303 citric acid monohydrate Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- JLVSRWOIZZXQAD-UHFFFAOYSA-N 2,3-disulfanylpropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(S)CS JLVSRWOIZZXQAD-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MMMUMTODVOCRFT-UHFFFAOYSA-N 2-[(oxolan-2-ylmethyldisulfanyl)methyl]oxolane Chemical compound C1CCOC1CSSCC1CCCO1 MMMUMTODVOCRFT-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 1
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 1
- 102000011131 Myosin-Light-Chain Phosphatase Human genes 0.000 description 1
- 108010037801 Myosin-Light-Chain Phosphatase Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000012494 forced degradation Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 229940113174 imidurea Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000012776 robust process Methods 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- QYNMSPKSYXPZHG-UHFFFAOYSA-M sodium;4-ethoxycarbonylphenolate Chemical compound [Na+].CCOC(=O)C1=CC=C([O-])C=C1 QYNMSPKSYXPZHG-UHFFFAOYSA-M 0.000 description 1
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Definitions
- the present invention relates to a stable oral liquid composition
- a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt, Guaifenesin, a chelating agent, sodium metabisulfite and at least one more pharmaceutically acceptable excipient.
- the invention further relates to a preparation of said composition and used thereof to relieve symptoms such as wheezing, shortness of breath, chest tightness, breathing difficulties, coughing, etc. associated with asthma by reducing bronchoconstriction.
- Terbutaline is chemically 5-[2-(tert-butylamino)-1 -hydroxyethyl] benzene-1 ,3-diol as shown in formula (I):
- Terbutaline is a (32 adrenergic receptor agonist. Agonism of these receptors in bronchioles activates adenylyl cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP), thus increased cAMP decreases intracellular calcium, activating protein kinase A, inactivating myosin light-chain kinase, activating myosin light-chain phosphatase, and finally relaxing smooth muscle in the bronchiole.
- cAMP cyclic adenosine monophosphate
- Terbutaline is used as a “reliever” inhaler in the management of asthma symptoms as mentioned here in above.
- Guaifenesin is 3-(2-methoxyphenoxy) propane-1 ,2-diol as shown in formula (II):
- Guaifenesin acts as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi in order to increase the efficiency of the cough reflex and facilitate removal of the secretions. Additionally, Guaifenesin has muscle relaxant and anticonvulsant properties and may act as an NMDA receptor antagonist. It is generally used in combination with other medications and is more effective particularly when taken by mouth.
- Bricanyl Expectorant® syrup for relieving cough by softening phlegm in the respiratory tract, widens the airway and facilitates breathing in patients with asthma or other similar diseases.
- Bricanyl Expectorant® can be taken for three times (10-15 ml) in one day in adult population.
- the dosage of Bricanyl Expectorant® should be adjusted by the total weight of the body in children and it should not be used in children less than 6 years. Since, it is used in children older than 6 years, the effectiveness and stability are significantly important.
- Bricanyl Expectorant® is a syrup that contains sorbitol, glycerin, citric acid, sodium hydroxide, sodium benzoate, disodium edetate, sodium saccharine, ethanol, methanol, raspberry flavor and deionized water.
- US 3937838 firstly discloses Terbutaline compound and its processes for preparation, pharmaceutical compositions and use thereof in the treatment of lung diseases such as bronchial asthma, chronic bronchitis, acute bronchospasm, asthma, bronchospasm prophylaxis and chronic obstructive pulmonary disease.
- US 4390732 firstly discloses Guaifenesin compound and its processes for preparation with good yield and purity.
- TR 2017/20846 discloses the pharmaceutical syrup composition
- Terbutaline sulfate in an amount of 0.01 % - 0.1 % and Guaifenesin in an amount of 0.1 - 8 % by the total weight of the composition and its manufacturing process.
- TR 2017/20845 discloses the pharmaceutical syrup composition comprising Terbutaline sulfate in an amount of 0.01 % - 0.1 % by the weight of the total composition and its manufacturing process.
- WO 2003068206 A1 discloses a pharmaceutical composition comprising a combination of a bronchodilator selected from salbutamol and terbutaline, or a pharmaceutically acceptable salt or derivative thereof, and guaifenesin, or a pharmaceutically acceptable salt or derivative thereof, as active ingredients.
- the inventors of the present invention have done the series of experiments and checked different agents, which are allowed to use in oral solution, to control the said oxidation impurity during the stability and surprisingly identified that Sodium metabisulfite has ability to control the said oxidation impurity that too without compromising the efficacy and potency of oral solution comprising Terbutaline and Guaifenesin. While selecting the suitable antioxidant, many trials have been performed by using known antioxidants including but not limited to Butylated Hydroxy Toluene, Butylated Hydroxy Anisole, etc. but satisfactory results have not been obtained.
- a main object of the present invention is to provide a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt and Guaifenesin, which has superior stability over the equivalent compositions known in the market.
- Another object of the present invention is to provide a stable oral liquid composition
- a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt and Guaifenesin, which contains acceptable amount of oxidation impurity as per ICH guideline.
- Yet another object of the present invention is to provide a stable oral liquid composition
- a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt and Guaifenesin, in which amount of oxidation impurity remains within specification over the period as per the ICH guideline.
- Yet another object of the present invention is to provide a stable oral liquid composition
- a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt and Guaifenesin, in which the use of Sodium metabisulfite doesn’t decrease the potency and efficacy of said composition.
- Yet another object of the present invention is to provide a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt and Guaifenesin, which overcomes the problems of the prior art.
- Yet another object of the invention is to provide a commercially scalable, cost effective, environment friendly and robust process for the preparation of oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt and Guaifenesin.
- the present invention provides a stable oral liquid composition
- a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt, Guaifenesin, a chelating agent, sodium metabisulfite and at least one more pharmaceutically acceptable excipient.
- the present invention provides a stable oral liquid composition
- a stable oral liquid composition comprising Terbutaline, which is present in the composition as a sulfate salt.
- the present invention provides a stable oral liquid composition
- a stable oral liquid composition comprising Terbutaline sulfate, which is present in an amount of 0.03% to 0.08% by weight of the total volume of the composition.
- the present invention provides a stable oral liquid composition comprising Guaifenesin, which is present in an amount of 0.5% to 3.0% by weight of the total volume of the composition.
- the present invention provides a stable oral liquid composition
- Sodium metabisulfite which is present in an amount of 0.03% to 0.07% by weight of the total volume of the composition.
- the present invention provides a stable oral liquid composition
- the chelating agent is disodium EDTA.
- the present invention provides a stable oral liquid composition
- a stable oral liquid composition comprising at least one more pharmaceutically acceptable excipient is selected from preservative, sweetening agent, viscosity agent and pH adjusting agent.
- the present invention provides a stable oral liquid composition, which is used to relieve symptoms such as wheezing, shortness of breath, chest tightness, breathing difficulties, coughing, etc. associated with asthma by reducing bronchoconstriction.
- oral liquid composition means a pharmaceutical composition which are homogeneous liquid preparations, usually consisting of a solution, an emulsion, or a suspension, of one or more active ingredients in a suitable liquid base. They are prepared for oral administration either as such or after dilution.
- Tebutaline as used in the present invention includes, but is not limited to, Terbutaline per se, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof, and also its various crystalline and amorphous forms.
- Guideaifenesin as used in the present invention includes, but is not limited to, Guaifenesin per se, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof, and also its various crystalline and amorphous forms.
- stable as used herein is intended to mean that a composition of a pharmaceutical product or a method of the present invention does not substantially decompose to form one or more degradation products when stored as per the ICH guideline for stability.
- oxidation impurity comes at RRT 0.88, more preferably less than 0.2% oxidation impurity (comes at RRT 0.88) and more preferably less than 0.1 % oxidation impurity (comes at RRT 0.88) identified when the composition of the present invention is stored as per the ICH guideline for stability.
- RRT refers to Relative Retention Time.
- impurities are identified spectroscopically and/or with another physical method, and then are associated with a peak position, such as that in a chromatogram, or with a spot on a TLC plate. Thereafter, the impurity can be identified, e.g., by its relative position in the chromatogram, where the position in a chromatogram is measured in minutes between injection of the sample on the column and elution of the particular component through the detector. The relative position in the chromatogram is known as the “retention time” (RT).
- Retention time can vary about a mean value based upon the condition of the instrumentation as well as many other factors.
- RRT relative retention time
- the RRT of an impurity is its retention time divided by the retention time of a reference marker.
- ICH guideline refers to International Conference on Harmonization guidelines.
- the impurity levels in any drug product are described as per its biological or toxicological data. It is quite important for “regulatory” aspect of drug approval also to provide limitation of “impurities.” Therefore, it is necessary to study the impurity profile of any formulation and control it during the manufacturing of a formulation.
- the liquid formulation even when stored with an inert surface (e.g., glass or canister) begins to deteriorate (i.e., formation of an oxidized impurity) when subjected to accelerated storage conditions (e.g., 40° C., 75% relative humidity for 3 months), indicating unsuitability of the product.
- accelerated storage conditions e.g. 40° C., 75% relative humidity for 3 months
- the level of oxidized impurity (after long-term storage) exceeds the qualification threshold and identification threshold calculated based on the maximum daily dosage.
- the inventors of the present invention have observed that amount of oxidation impurity, derived from the oxidation of Terbutaline compound comes at RRT 0.88, is out of the specification in innovator’s marketed composition as well as equivalent compositions.
- the inventors of the present invention have surprisingly identified that sodium metabisulfite effectively controlled the said oxidation impurity as compared to other antioxidant such as Butylated Hydroxy Toluene (BHT), Butylated Hydroxy Anisole (BHA), etc.
- the present invention provides a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt, Guaifenesin, a chelating agent, sodium metabisulfite and at least one more pharmaceutically acceptable excipient.
- a stable oral liquid composition of the present invention comprises Terbutaline as a sulfate salt.
- a stable oral liquid composition of the present invention comprises Terbutaline in an amount of 0.03 % to 0.08 %, more preferably 0.06 % by weight of the total volume of the composition.
- an oral liquid composition of the present invention comprises Guaifenesin in an amount of 0.5 % to 3.0 %, more preferably 1 .3 % by weight of the total volume of the composition.
- an oral liquid composition of the present invention comprises sodium metabisulfite in an amount of 0.03% to 0.07%, more preferably 0.05 % by weight of the total volume of the composition.
- an oral liquid composition of the present invention comprises chelating agent which is disodium EDTA.
- Chelating agents are chemical compounds that react with metal ions to form a stable, water-soluble complex. They are also known as chelates, chelators, or sequestering agents. Chelating agents includes but are not limited to, ethylenediaminetetraacetic acid (EDTA), 2,3-dimercaptopropanesulfonic acid (DMPS), and thiamine tetrahydrofurfuryl disulfide (TTFD).
- EDTA ethylenediaminetetraacetic acid
- DMPS 2,3-dimercaptopropanesulfonic acid
- TTFD thiamine tetrahydrofurfuryl disulfide
- the chelating agent can be used in amount from 0.1 % to 0.5% by weight of the total volume of the composition.
- EDTA is preferred chelating agent.
- an oral liquid composition of the present invention comprises at least one more pharmaceutically acceptable excipient is selected from preservative, sweetening agent, viscosity agent and pH adjusting agent
- Preservative includes but are not limited to, sodium benzoate, cresol, ethylparaben, glycerin, hexetidine, imidurea, methylparaben, monothioglycerol, phenol, phenoxyethanol, phenylmercuric acetate, potassium benzoate, propionic acid, propylene glycol, sodium ethyl paraben, sodium propyl paraben and benzalkonium chloride.
- the preservative can be used in amount from 0.01 % to 0.2% by weight of the total volume of the composition.
- preferably sodium benzoate is used as preservative.
- Sweetening agents includes but are not limited to, acesulfame K, aspartame, dextrose, fructose, galactose, inulin, maltitol, maltose, mannitol, saccharin, sodium cyclamate, sorbitol, sucralose, sucrose, trehalose, xylitol.
- the sweetening agent can be used in amount from 20% to 30-% by weight of the total volume of the composition.
- preferably sodium saccharine is used as sweetening agent.
- Viscosity agents includes but are not limited to, glycerin, carboxymethylcellulose sodium NF, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium aluminum silicate, poloxamer, polyethylene Oxide, polyvinyl Alcohol, povidone, propylene glycol alginate, silicon dioxide, sodium alginate.
- the viscosity agent can be used in amount from 15% to 25% by weight of the total volume of the composition. In the present invention, preferably glycerin is used as viscosity agent.
- pH adjusting agents includes but are not limited to acetic acid, hydrobromic acid, citric acid, gluconic acid, potassium acetate, sodium hydroxide, hydrochloric acid, sulfuric acid, potassium sulfate, barium carbonate.
- the pH adjusting agent can be used in enough amount until pH reaches 4.0-5.0.
- preferably sodium hydroxide is used as pH adjusting agent.
- the oral liquid composition of the present invention is prepared by dissolving of Terbutaline sulfate and Guaifenesin in water by heating and then excipients are added into the solution in suitable manner.
- the oral liquid composition of the present invention is intended for oral use and it is in the form of syrup.
- the oral liquid composition of the present invention is used as a medicament for relieving cough by softening phlegm in the respiratory tract, widens the airway and facilitates breathing in patients with asthma or other similar diseases.
- Example 1 An oral liquid composition comprising Terbutaline sulfate and Guaifenesin
- Sorbitol, glycerol, sodium saccharin, sodium benzoate and citric acid monohydrate were added in sequential manner and mixed until dissolved.
- Example-2 Preparation of an oral liquid composition comprising Terbutaline sulfate and Guaifenesin by nitrogen purging
- the inventors of the present invention produced an oral liquid composition under the nitrogen gas to control the oxidation impurity comes at RRT 0.88. However, it is evident that the said oxidation impurity has been increased after 7 days when stored under normal condition and that too out of set specification.
- Example-3 An oral liquid composition comprising Terbutaline sulfate, Guaifenesin and sodium metabisulfite
- Citric acid Monohydrate was added and mixed until dissolved.
- the oral liquid composition of the present invention has been produced under the nitrogen gas during manufacturing process with sodium metabisulfite in an amount of 0.05 % by weight of the total weight of the composition. Then impurity profiles has been checked at initial stage and after 6 days. Table 6
- Example-4 Stability of oral liquid composition of Example-3
- Example-5 Comparative Stability analysis of oral liquid composition of Example-3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt, Guaifenesin, a chelating agent, sodium metabisulfite and at least one more pharmaceutically acceptable excipient. The invention further relates to a preparation of said composition and used thereof to relieve symptoms such as wheezing, shortness of breath, chest tightness, breathing difficulties, coughing, etc. associated with asthma by reducing bronchoconstriction.
Description
A STABLE ORAL LIQUID COMPOSITION COMPRISING TERBUTALINE & GUAIFENESIN
FIELD OF THE INVENTION
The present invention relates to a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt, Guaifenesin, a chelating agent, sodium metabisulfite and at least one more pharmaceutically acceptable excipient. The invention further relates to a preparation of said composition and used thereof to relieve symptoms such as wheezing, shortness of breath, chest tightness, breathing difficulties, coughing, etc. associated with asthma by reducing bronchoconstriction.
BACKGROUND OF THE INVENTION
Terbutaline is chemically 5-[2-(tert-butylamino)-1 -hydroxyethyl] benzene-1 ,3-diol as shown in formula (I):
Terbutaline is a (32 adrenergic receptor agonist. Agonism of these receptors in bronchioles activates adenylyl cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP), thus increased cAMP decreases intracellular calcium, activating protein kinase A, inactivating myosin light-chain kinase, activating myosin light-chain phosphatase, and finally relaxing smooth muscle in the bronchiole. Terbutaline is used as a “reliever” inhaler in the management of asthma symptoms as mentioned here in above.
Guaifenesin is 3-(2-methoxyphenoxy) propane-1 ,2-diol as shown in formula (II):
It is an expectorant commonly used for the symptomatic relief from congested chests and coughs associated with cold, bronchitis, and/or other breathing illnesses. Guaifenesin acts as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi in order to increase the efficiency of the cough reflex and facilitate removal of the secretions. Additionally, Guaifenesin has muscle relaxant and anticonvulsant properties and may act as an NMDA receptor antagonist. It is generally used in combination with other medications and is more effective particularly when taken by mouth.
The combination of Terbutaline (as a sulfate salt) and Guaifenesin is well known combination and marketed under the tradename of Bricanyl Expectorant® syrup for relieving cough by softening phlegm in the respiratory tract, widens the airway and facilitates breathing in patients with asthma or other similar diseases. Bricanyl Expectorant® can be taken for three times (10-15 ml) in one day in adult population. The dosage of Bricanyl Expectorant® should be adjusted by the total weight of the body in children and it should not be used in children less than 6 years. Since, it is used in children older than 6 years, the effectiveness and stability are significantly important.
Bricanyl Expectorant® is a syrup that contains sorbitol, glycerin, citric acid, sodium hydroxide, sodium benzoate, disodium edetate, sodium saccharine, ethanol, methanol, raspberry flavor and deionized water.
US 3937838 firstly discloses Terbutaline compound and its processes for preparation, pharmaceutical compositions and use thereof in the treatment of lung diseases such as bronchial asthma, chronic bronchitis, acute bronchospasm, asthma, bronchospasm prophylaxis and chronic obstructive pulmonary disease.
US 4390732 firstly discloses Guaifenesin compound and its processes for preparation with good yield and purity.
TR 2017/20846 discloses the pharmaceutical syrup composition comprising Terbutaline sulfate in an amount of 0.01 % - 0.1 % and Guaifenesin in an amount of 0.1 - 8 % by the total weight of the composition and its manufacturing process.
TR 2017/20845 discloses the pharmaceutical syrup composition comprising Terbutaline sulfate in an amount of 0.01 % - 0.1 % by the weight of the total composition and its manufacturing process.
WO 2003068206 A1 discloses a pharmaceutical composition comprising a combination of a bronchodilator selected from salbutamol and terbutaline, or a pharmaceutically acceptable salt or derivative thereof, and guaifenesin, or a pharmaceutically acceptable salt or derivative thereof, as active ingredients.
Without binding to any theory, it is believed that use of preservative and chelating agent in marketed composition of Bricanyl Expectorant® is to control the degradation impurity, particularly oxidation impurity, which arises from the oxidation Terbutaline. However, when we have checked the impurity level of innovator’s marketed composition along with other equivalent products available in market, we observed that level of said oxidation impurity, which is coming at RRT 0.88, is out of expected limit set by ICH.
Thus, there still exist a need of getting a stable and efficient composition without compromising the efficacy and potency of the said composition.
To overcome this problem, the inventors of the present invention have done the series of experiments and checked different agents, which are allowed to use in oral solution, to control the said oxidation impurity during the stability and surprisingly identified that Sodium metabisulfite has ability to control the said oxidation impurity that too without compromising the efficacy and potency of oral solution comprising Terbutaline and
Guaifenesin. While selecting the suitable antioxidant, many trials have been performed by using known antioxidants including but not limited to Butylated Hydroxy Toluene, Butylated Hydroxy Anisole, etc. but satisfactory results have not been obtained.
OBJECT OF THE INVENTION
A main object of the present invention is to provide a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt and Guaifenesin, which has superior stability over the equivalent compositions known in the market.
Another object of the present invention is to provide a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt and Guaifenesin, which contains acceptable amount of oxidation impurity as per ICH guideline.
Yet another object of the present invention is to provide a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt and Guaifenesin, in which amount of oxidation impurity remains within specification over the period as per the ICH guideline.
Yet another object of the present invention is to provide a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt and Guaifenesin, in which the use of Sodium metabisulfite doesn’t decrease the potency and efficacy of said composition.
Yet another object of the present invention is to provide a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt and Guaifenesin, which overcomes the problems of the prior art.
Yet another object of the invention is to provide a commercially scalable, cost effective, environment friendly and robust process for the preparation of oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt and Guaifenesin.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt, Guaifenesin, a chelating agent, sodium metabisulfite and at least one more pharmaceutically acceptable excipient.
In another aspect, the present invention provides a stable oral liquid composition comprising Terbutaline, which is present in the composition as a sulfate salt.
In yet another aspect, the present invention provides a stable oral liquid composition comprising Terbutaline sulfate, which is present in an amount of 0.03% to 0.08% by weight of the total volume of the composition.
In yet another aspect, the present invention provides a stable oral liquid composition comprising Guaifenesin, which is present in an amount of 0.5% to 3.0% by weight of the total volume of the composition.
In yet another aspect, the present invention provides a stable oral liquid composition comprising Sodium metabisulfite, which is present in an amount of 0.03% to 0.07% by weight of the total volume of the composition.
In yet another aspect, the present invention provides a stable oral liquid composition comprising the chelating agent is disodium EDTA.
In yet another aspect, the present invention provides a stable oral liquid composition comprising at least one more pharmaceutically acceptable excipient is selected from preservative, sweetening agent, viscosity agent and pH adjusting agent.
In yet another aspect, the present invention provides a stable oral liquid composition, which is used to relieve symptoms such as wheezing, shortness of breath, chest
tightness, breathing difficulties, coughing, etc. associated with asthma by reducing bronchoconstriction.
The details of one or more embodiments of the present invention are set forth in the description below. Other features, objects and advantages of the invention will be apparent from the description.
DETAILED DESCRIPTION OF THE PRESENT INVENTION
The present invention will now be more specifically illustrated as hereunder.
In the present invention, unless indicated otherwise, all ingredient concentrations are presented in units of % weight/volume (% w/v).
The term "about" can indicate a difference of 10 percent of the value specified. Numerical ranges as used herein are meant to include every number and subset of numbers enclosed within that range, whether particularly disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range.
The term “oral liquid composition” as used in the present invention means a pharmaceutical composition which are homogeneous liquid preparations, usually consisting of a solution, an emulsion, or a suspension, of one or more active ingredients in a suitable liquid base. They are prepared for oral administration either as such or after dilution.
The term “Terbutaline” as used in the present invention includes, but is not limited to, Terbutaline per se, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof, and also its various crystalline and amorphous forms.
The term “Guaifenesin” as used in the present invention includes, but is not limited to, Guaifenesin per se, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof, and also its various crystalline and amorphous forms.
The term “stable” as used herein is intended to mean that a composition of a pharmaceutical product or a method of the present invention does not substantially decompose to form one or more degradation products when stored as per the ICH guideline for stability. For example, there is not more than 0.3% oxidation impurity comes at RRT 0.88, more preferably less than 0.2% oxidation impurity (comes at RRT 0.88) and more preferably less than 0.1 % oxidation impurity (comes at RRT 0.88) identified when the composition of the present invention is stored as per the ICH guideline for stability.
The term “RRT” refers to Relative Retention Time. Generally, impurities are identified spectroscopically and/or with another physical method, and then are associated with a peak position, such as that in a chromatogram, or with a spot on a TLC plate. Thereafter, the impurity can be identified, e.g., by its relative position in the chromatogram, where the position in a chromatogram is measured in minutes between injection of the sample on the column and elution of the particular component through the detector. The relative position in the chromatogram is known as the “retention time” (RT).
Retention time can vary about a mean value based upon the condition of the instrumentation as well as many other factors. To mitigate the effects such variations have upon accurate identification of an impurity, those skilled in the art use the “relative retention time” (RRT) to identify impurities. The RRT of an impurity is its retention time divided by the retention time of a reference marker.
The term “ICH guideline” refers to International Conference on Harmonization guidelines. The impurity levels in any drug product are described as per its biological or toxicological data. It is quite important for “regulatory” aspect of drug approval also to provide limitation of “impurities.” Therefore, it is necessary to study the impurity profile of any formulation and control it during the manufacturing of a formulation. According to ICH guideline, the liquid formulation, even when stored with an inert surface (e.g., glass or canister) begins to deteriorate (i.e., formation of an oxidized impurity) when subjected to accelerated storage conditions (e.g., 40° C., 75% relative humidity for 3 months), indicating unsuitability of the product. Although present in small amounts, the level of oxidized impurity (after long-term storage) exceeds the qualification threshold and identification threshold calculated based on the maximum daily dosage. (See, ICH Guidance for Industry Q3B® Impurities in New Drug Products, November, 2003).
The inventors of the present invention have observed that amount of oxidation impurity, derived from the oxidation of Terbutaline compound comes at RRT 0.88, is out of the specification in innovator’s marketed composition as well as equivalent compositions. To overcome the problem associated with increased amount of said oxidation impurity generated during the manufacturing and stability, the inventors of the present invention have surprisingly identified that sodium metabisulfite effectively controlled the said oxidation impurity as compared to other antioxidant such as Butylated Hydroxy Toluene (BHT), Butylated Hydroxy Anisole (BHA), etc.
Besides that it has also been observed that due to the low solubility of BHT & BHA, precipitation occurred in the solution after the adding BHT & BHA into the composition separately. In contrast, while the addition of sodium metabisulfite to the solution don’t allow solution to be precipitated and provided a clear solution.
Shortly, it has been surprisingly found that while sodium metabisulfite has been used as an antioxidant at a specific concentration in the liquid composition of the present invention provides a syrup with better stability results and desired impurity profile as compared to reference product (Bricanyl Expectorant®).
In general embodiment, the present invention provides a stable oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt, Guaifenesin, a chelating agent, sodium metabisulfite and at least one more pharmaceutically acceptable excipient.
In embodiments, a stable oral liquid composition of the present invention comprises Terbutaline as a sulfate salt.
In embodiments, a stable oral liquid composition of the present invention comprises Terbutaline in an amount of 0.03 % to 0.08 %, more preferably 0.06 % by weight of the total volume of the composition.
In embodiments, an oral liquid composition of the present invention comprises Guaifenesin in an amount of 0.5 % to 3.0 %, more preferably 1 .3 % by weight of the total volume of the composition.
In embodiments, an oral liquid composition of the present invention comprises sodium metabisulfite in an amount of 0.03% to 0.07%, more preferably 0.05 % by weight of the total volume of the composition.
In embodiments, an oral liquid composition of the present invention comprises chelating agent which is disodium EDTA.
Chelating agents are chemical compounds that react with metal ions to form a stable, water-soluble complex. They are also known as chelates, chelators, or sequestering agents. Chelating agents includes but are not limited to, ethylenediaminetetraacetic acid (EDTA), 2,3-dimercaptopropanesulfonic acid (DMPS), and thiamine tetrahydrofurfuryl disulfide (TTFD). The chelating agent can be used in amount from 0.1 % to 0.5% by weight of the total volume of the composition. In the present invention, EDTA is preferred chelating agent.
In embodiments, an oral liquid composition of the present invention comprises at least one more pharmaceutically acceptable excipient is selected from preservative, sweetening agent, viscosity agent and pH adjusting agent.
Preservative includes but are not limited to, sodium benzoate, cresol, ethylparaben, glycerin, hexetidine, imidurea, methylparaben, monothioglycerol, phenol, phenoxyethanol, phenylmercuric acetate, potassium benzoate, propionic acid, propylene glycol, sodium ethyl paraben, sodium propyl paraben and benzalkonium chloride. The preservative can be used in amount from 0.01 % to 0.2% by weight of the total volume of the composition. In the present invention, preferably sodium benzoate is used as preservative.
Sweetening agents includes but are not limited to, acesulfame K, aspartame, dextrose, fructose, galactose, inulin, maltitol, maltose, mannitol, saccharin, sodium cyclamate, sorbitol, sucralose, sucrose, trehalose, xylitol. The sweetening agent can be used in amount from 20% to 30-% by weight of the total volume of the composition. In the present invention, preferably sodium saccharine is used as sweetening agent.
Viscosity agents includes but are not limited to, glycerin, carboxymethylcellulose sodium NF, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium aluminum silicate, poloxamer, polyethylene Oxide, polyvinyl Alcohol, povidone, propylene glycol alginate, silicon dioxide, sodium alginate. The viscosity agent can be used in amount from 15% to 25% by weight of the total volume of the composition. In the present invention, preferably glycerin is used as viscosity agent. pH adjusting agents includes but are not limited to acetic acid, hydrobromic acid, citric acid, gluconic acid, potassium acetate, sodium hydroxide, hydrochloric acid, sulfuric acid, potassium sulfate, barium carbonate. The pH adjusting agent can be used in enough amount until pH reaches 4.0-5.0. In the present invention, preferably sodium hydroxide is used as pH adjusting agent.
The oral liquid composition of the present invention is prepared by dissolving of Terbutaline sulfate and Guaifenesin in water by heating and then excipients are added into the solution in suitable manner.
The oral liquid composition of the present invention is intended for oral use and it is in the form of syrup.
The oral liquid composition of the present invention is used as a medicament for relieving cough by softening phlegm in the respiratory tract, widens the airway and facilitates breathing in patients with asthma or other similar diseases.
The following examples are intended to illustrate the scope of the present invention but not to limit it thereto.
Examples:
Example 1 : An oral liquid composition comprising Terbutaline sulfate and Guaifenesin
Table-1
Manufacturing Process:
1. Water up to 50% of the production batch was transferred into the production tank and heated to 30-35°C. 5% of water out of the total quantity was kept reserved for washing.
2. Guaifenesin was added to water and mixed until it dissolved. Heating process was terminated after the dissolution process was completed.
3. EDTA was added and mixed until dissolved.
4. Added sodium metabisulfite and mixed until dissolved.
5. Terbutaline was added and mixed until dissolved.
6. Then Sorbitol, glycerol, sodium saccharin, sodium benzoate and citric acid monohydrate were added in sequential manner and mixed until dissolved.
7. Menthol and strawberry flavor were dissolved in alcohol and added to the production tank and mixed.
8. Rest of the amount of water was added to complete the volume and the product was mixed for at least 15 minutes. (pH is controlled and final pH should be between 4.1 -4.3)
The impurity profiles of the composition of table-1 have been checked at below mentioned conditions.
Table 2
It is evident from the table-2 that level of oxidation impurity at RRT 0.88 is more than 0.2% at initial stage and increased over the time when composition has been prepared without using an antioxidant like sodium metabisulfite.
Example-2: Preparation of an oral liquid composition comprising Terbutaline sulfate and Guaifenesin by nitrogen purging
Table 3
Manufacturing Process:
1. Water up to 50% of the production batch was transferred into the production tank and heated to 30-35°C. 5% of water out of the total quantity was kept reserved for washing.
2. Guaifenesin was added to water and mixed until it dissolved. Heating process was terminated after the dissolution process was completed.
3. EDTA was added and mixed until dissolved.
4. Added sodium metabisulfite and mixed until dissolved.
5. Terbutaline was added and mixed until dissolved.
6. Sorbitol, glycerol, sodium saccharin, sodium benzoate and citric acid monohydrate were added and mixed until dissolved.
7. Menthol and strawberry flavor were dissolved in alcohol and added to the production tank and mixed.
8. Rest of the amount of water was added to complete the volume and the product was mixed for at least 15 minutes. (pH is controlled and final pH should be between 4.1 -4.3)
The impurity profiles of the composition of table-3 have been checked at below mentioned conditions.
Table 4
As per the conventional approach, the inventors of the present invention produced an oral liquid composition under the nitrogen gas to control the oxidation impurity comes at RRT 0.88. However, it is evident that the said oxidation impurity has been increased after 7 days when stored under normal condition and that too out of set specification.
Example-3: An oral liquid composition comprising Terbutaline sulfate, Guaifenesin and sodium metabisulfite
Table 5
Manufacturing Process:
1. Water up to 50% of the production batch was transferred into the production tank and heated to 30-35°C. 5% of water was kept reserved for washing.
2. Guaifenesin was added to water and mixed until it dissolved. Heating process was terminated after the dissolution process was completed.
3. EDTA was added and mixed until dissolved.
4. Added sodium metabisulfite and mixed until dissolved.
5. Terbutaline was added and mixed until dissolved.
6. Sorbitol was added and mixed until dissolved.
7. Glycerol was added and mixed until dissolved.
8. Sodium Saccharin was added and mixed until dissolved.
9. Sodium Benzoate was added and mixed until dissolved.
10. Citric acid Monohydrate was added and mixed until dissolved.
11. Menthol and strawberry flavor were dissolved in alcohol and added to the production tank and mixed.
12. Rest of the amount of water was added to complete the volume and the product was mixed for at least 15 minutes. (pH is controlled and final pH should be between 4.1 -4.3)
The oral liquid composition of the present invention has been produced under the nitrogen gas during manufacturing process with sodium metabisulfite in an amount of 0.05 % by weight of the total weight of the composition. Then impurity profiles has been checked at initial stage and after 6 days.
Table 6
It is evident from Table 6 that use of sodium metabisulfite effectively control the oxidation impurity comes at RRT 0.88.
Example-4: Stability of oral liquid composition of Example-3
An oral liquid composition prepared as per the example-3 has also been checked under the forced degradation condition i.e. with 3% H2O2 for 4 hour and with %30 H2O2 for 2 hours to see the anti-oxidant effects of sodium metabisulfite over the generation of oxidation impurity comes at RRT 0.88. It can be seen from Table 8, there is no oxidation impurity (comes at RRT 0.88) detected even after the treatment of 30% H2O2.
Table 8
Example-5: Comparative Stability analysis of oral liquid composition of Example-3
An impurity profile of the present invention (at initial stage) has been analyzed and compared with along with innovator’s marketed composition and other equivalent compositions, which are provided here in below table-7.
Table 7
Claims
1. An oral liquid composition comprising Terbutaline or its pharmaceutically acceptable salt, Guaifenesin, a chelating agent, sodium metabisulfite and at least one more pharmaceutically acceptable excipient.
2. An oral liquid composition according to claim 1 , wherein Terbutaline is present in the composition as sulfate salt.
3. An oral liquid composition according to claim 1 , wherein Terbutaline sulfate is present in an amount of 0.03 % to 0.08% by weight of the total volume of the composition.
4. An oral liquid composition according to claim 1 , wherein Guaifenesin is present in an amount of 0.5% to 3.0% by weight of the total volume of the composition.
5. An oral liquid composition according to claim 1 , wherein sodium metabisulfite is present in an amount of 0.03% to 0.07% by weight of the total volume of the composition.
6. An oral liquid composition according to claim 1 or claim 5, wherein sodium metabisulfite is present in an amount of 0.05% by weight of the total volume of the composition.
7. An oral liquid composition according to claim 1 , wherein the chelating agent is disodium EDTA.
8. An oral liquid composition according to claim 1 , wherein at least one more pharmaceutically acceptable excipient is selected from preservative, sweetening agent, viscosity agent and pH adjusting agent.
9. An oral liquid composition according to claim 1 is used to relieve symptoms such as wheezing, shortness of breath, chest tightness, breathing difficulties, coughing, etc. associated with asthma by reducing bronchoconstriction.
O.An oral liquid composition according to claim 1 comprising an oxidation impurity comes at RRT 0.88 less than 0.3%.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2022010733 | 2022-06-29 | ||
| TR2022/010733 TR2022010733A1 (en) | 2022-06-29 | STABLE ORAL LIQUID COMPOSITION CONTAINING TERBUTALINE AND GUAIFENESIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024005758A1 true WO2024005758A1 (en) | 2024-01-04 |
Family
ID=89380996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2023/050605 WO2024005758A1 (en) | 2022-06-29 | 2023-06-21 | A stable oral liquid composition comprising terbutaline & guaifenesin |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024005758A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0185291B1 (en) * | 1996-06-10 | 1999-05-01 | 김태훈 | Extended release composition containing terbutaline sulfate and guaifenesin(2) |
| WO2003030877A1 (en) * | 2001-10-10 | 2003-04-17 | The Procter & Gamble Company | Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer |
-
2023
- 2023-06-21 WO PCT/TR2023/050605 patent/WO2024005758A1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0185291B1 (en) * | 1996-06-10 | 1999-05-01 | 김태훈 | Extended release composition containing terbutaline sulfate and guaifenesin(2) |
| WO2003030877A1 (en) * | 2001-10-10 | 2003-04-17 | The Procter & Gamble Company | Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer |
Non-Patent Citations (1)
| Title |
|---|
| KIMBAHUNE R; SUNIL K; KABRA P; DELVADIYA K; SURANI S: "Spectrophotometric simultaneous analysis of Ambroxol hydrochloride, Guaifenesin and Terbutaline sulphate in liquid dosage form (syrup)", INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES REVIEW AND RESEARCH, GLOBAL RESEARCH ONLINE PUBLISHING HOUSE, IN, vol. 8, no. 2, 30 April 2011 (2011-04-30), IN , pages 24 - 28, XP009502376, ISSN: 0976-044X * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9308200B2 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| US9220693B2 (en) | Aqueous composition comprising bromhexine | |
| US20160089339A1 (en) | Capsule formulation comprising montelukast and levocetirizine | |
| US20120323178A1 (en) | Bepotastine compositions | |
| NO328423B1 (en) | Drug compositions based on anti-cholinergically effective compounds and β-mimetics as well as their use in the manufacture of drugs for the treatment of diseases. | |
| EP3612173B1 (en) | Epinephrine spray formulations | |
| US20090192187A1 (en) | Dry powder formulation comprising an anticholinergic drug | |
| TWI589305B (en) | Liquid formulation for oral administration comprising ambroxol, levodropropizine and buffering agent, and method for preparing the same | |
| EP1496882B1 (en) | Tolterodine salts | |
| US20210322311A1 (en) | Inhalable Formulation of a Solution Containing Tiotropium Bromide and Olodaterol | |
| JP5214966B2 (en) | Formulation of 2-amino-1,3-propanediol compound and analogs thereof | |
| US20110166149A1 (en) | Pteridine derivatives for treating respiratory disease | |
| US20120220557A1 (en) | Liquid propellant-free formulation comprising an antimuscarinic drug | |
| WO2024005758A1 (en) | A stable oral liquid composition comprising terbutaline & guaifenesin | |
| US7319095B2 (en) | Use of GABAB receptor agonists | |
| EP3416654B1 (en) | Medical use of 5'-adenosine diphosphate ribose (adpr) | |
| TR2022010733A1 (en) | STABLE ORAL LIQUID COMPOSITION CONTAINING TERBUTALINE AND GUAIFENESIN | |
| GB2596592A (en) | Pharmaceutical formulation | |
| KR102447263B1 (en) | Cough medicine containing ambroxol hydrochloride | |
| WO2018182546A1 (en) | Stabilized pharmaceutical syrup composition comprising terbutaline sulphate and ambroxol hydrochloride | |
| WO2007107835A2 (en) | Stable liquid formulations of antiepileptic agents | |
| US20060160777A1 (en) | New use of GABAbeta receptor agonists | |
| US20210322310A1 (en) | Inhalable Formulation of a Solution Containing Tiotropium Bromide | |
| US20190336478A1 (en) | Stable oral liquid compositions of enalapril | |
| CN114191386A (en) | Preparation method of bosentan oral solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23832042 Country of ref document: EP Kind code of ref document: A1 |